: Antibody-drug conjugates are redefining treatment options in advanced breast cancer, demonstrating efficacy across all breast cancer subtypes. However, their rapid clinical expansion has resulted in several unresolved challenges, including the need for rational sequencing strategies, appropriate and ethical trial design, drug tolerability, and the limitation of mono-national development programs.
Beyond the hype: Antibody-Drug Conjugates are advancing faster than our clinical strategy / Notini, G.; Bianchini, G.; Pérez-García, J. M.; Cortés, J.. - In: PLOS MEDICINE. - ISSN 1549-1676. - 23:1(2026). [10.1371/journal.pmed.1004930]
Beyond the hype: Antibody-Drug Conjugates are advancing faster than our clinical strategy
Notini G.Primo
;Bianchini G.Secondo
;
2026-01-01
Abstract
: Antibody-drug conjugates are redefining treatment options in advanced breast cancer, demonstrating efficacy across all breast cancer subtypes. However, their rapid clinical expansion has resulted in several unresolved challenges, including the need for rational sequencing strategies, appropriate and ethical trial design, drug tolerability, and the limitation of mono-national development programs.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
